Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • Lamivudine is appropriate for use in persons coinfected with HIV and HBV if administered in combination with other agents with anti-HBV activity in the context of an antiretroviral therapy regimen and at the dose used in the treatment of HIV (300 mg daily) (Management Guidelines)[DHHS ART]
  • Incidence of lamivudine-resistant HBV is approximately 20% per year in people with HIV if taken as monotherapy for HBV and reaches 90% at 4 years[Dore 1999; Benhamou 1999; Pillay 2000]

Action required